Pharmacoeconomics of adalimumab for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn’s disease

References

• Humira®, package insert. Abbott Laboratories, Abbott Park, IL, USA (2007).
   Google Scholar
• Rau R. Adalimumab (a fully human anti-tumour necrosis factor a monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann. Rheum. Dis.61(Suppl. 3), ii70–ii73 (2002).
   PubMed Web of Science ®Google Scholar
• Van de Putte LB, Rau R, Breedveld FC et al. Efficacy and safety of the fully human anti-tumour necrosis factor a monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, Phase II study. Ann. Rheum. Dis.62(12), 1168–1177 (2003).
   PubMed Web of Science ®Google Scholar
• Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics22(Suppl. 2), 1–12 (2004).
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum.46, 328–346 (2002).
   PubMedGoogle Scholar
• Yelin E, Callahan LF. The economic cost and social and psychological impact of musculoskeletal conditions. National Arthritis Data Work Groups. Arthritis Rheum.38(10), 1351–1362 (1995).
   PubMed Web of Science ®Google Scholar
• Pincus T, Callahan LF. The side effects of rheumatoid arthritis: joint destruction, disability and early mortality. Br. J. Rheumatol.32(Suppl. 1), 28–37 (1993).
   PubMedGoogle Scholar
• Wong JB, Ramey DR, Singh G. Long-term morbidity, mortality, and economics of rheumatoid arthritis. Arthritis Rheum.44(12), 2746–2749 (2001).
   PubMed Web of Science ®Google Scholar
• Coll J, Rives A, Griñó MC, Setoain J, Vivancos J, Balcells A. Prevalence of Sjögren’s syndrome in autoimmune diseases. Ann. Rheum. Dis.46(4), 286–289 (1987).
   PubMed Web of Science ®Google Scholar
• Piper H, Douglas KM, Treharne GJ, Mitton DL, Haider S, Kitas GD. Prevalence and predictors of ocular manifestations of RA: is there a need for routine screening? Musculoskeletal Care5(2), 102–117 (2007).
   PubMedGoogle Scholar
• Matteson EL, Cohen MD, Conn DL. Clinical features and systemic involvement. In: Rheumatology (2nd Edition). Klippel JH, Dieppe PA (Eds). Mosby, PA, USA, 5.4.4 (1988).
   Google Scholar
• Wolheim FA. Rheumatoid arthritis the clinical picture. In: Oxford Textbook of Rheumatology (2nd Edition). Maddison PJ, Isenberg DA, Woo P, Glass DN (Eds). Oxford University Press, NY, USA, 1010 (1998).
   Google Scholar
• Ekim A, Armagan O, Tascioglu F, Oner C, Colak M. Effect of low level laser therapy in rheumatoid arthritis patients with carpal tunnel syndrome. Swiss Med. Wkly137(23–24), 347–352 (2007).
   PubMed Web of Science ®Google Scholar
• Dickens C, McGowan L, Clark-Carter D, Creed F. Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. Psychosom. Med.64, 52–60 (2002).
   PubMed Web of Science ®Google Scholar
• Pincus T, Griffith J, Pearce S, Isenberg D. Prevalence of self-reported depression in patients with rheumatoid arthritis. Br. J. Rheumatol.35, 879–883 (1996).
   PubMedGoogle Scholar
• Keystone ED, Kavanaugh AF, Sharp JT et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. Arthritis Rheum.50, 1400–1411 (2004).
   PubMed Web of Science ®Google Scholar
• Kitas GD, Erb N. Tackling ischaemic heart disease in rheumatoid arthritis. Rheumatology42, 607–613 (2003).
   PubMed Web of Science ®Google Scholar
• Jacobsson LT, Turesson C, Gulfe A et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J. Rheumatol.32, 1213–1218 (2005).
   PubMed Web of Science ®Google Scholar
• Boers M, Verhoeven AC, Markusse HM et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet350(9074), 309–318 (1997).
   PubMed Web of Science ®Google Scholar
• Goekoop-Ruiterman YP, Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum.52(11), 3381–3390 (2005).
   PubMed Web of Science ®Google Scholar
• Grigor C, Capell H, Stirling A et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind, randomised, controlled trial. Lancet364(9430), 263–269 (2004).
   PubMed Web of Science ®Google Scholar
• Pincus T, Marcum SB, Callahan LF. Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J. Rheumatol.19, 1885–1894 (1992).
   PubMed Web of Science ®Google Scholar
• Klareskog L, Moreland LW, Cohen SB et al. The safety and efficacy of over seven years of continuous etanercept therapy in patients with rheumatoid arthritis in North America and Europe. Ann. Rheum. Dis.64(Suppl. 3), 410 (2005) (Abstract).
   Google Scholar
• Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med.343, 1594–1602 (2000).
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum.48(1), 35–45 (2003).
   PubMed Web of Science ®Google Scholar
• Furst DE, Schiff MH, Fleischmann RM et al. Adalimumab, a fully human anti tumor necrosis factor-a monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J. Rheumatol.30(12), 2563–2571 (2003).
   PubMed Web of Science ®Google Scholar
• van de Putte LB, Atkins C, Malaise M et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis.63(5), 508–516 (2004).
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum.54(1), 26–37 (2006).
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. Long-term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4-year extended study. Ann. Rheum. Dis.65, 753–759 (2006).
   PubMed Web of Science ®Google Scholar
• Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA) – an analysis of 220 patients. Q. J. Med.62, 127–141 (1987).
   PubMedGoogle Scholar
• Torre Alonso JC, Rodriguez PA, Arribas Castrillo JM et al. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br. J. Rheumatol.30, 245–250 (1991).
   PubMedGoogle Scholar
• Brockbank J, Schentag CT, Rosen C et al. Psoriatic arthritis (PsA) is common among patients with psoriasis and family medicine clinic attendees. Arthritis Rheum.44(Suppl. 94), (2001) (Abstract 249).
   Google Scholar
• Gladman D. Psoriatic arthritis. In: Oxford Textbook of Rheumatology (3rd Edition). Isenberg DA, Maddison PJ, Woo P, Glass DN, Breedveld F (Eds.), Oxford University Press, Oxford, UK, 644 (2004).
   Google Scholar
• Salvarani C, Lo SG, Macchioni P et al. Prevalence of psoriatic arthritis in Italian psoriatic patients. J. Rheumatol.22, 1499–1503 (1995).
   PubMed Web of Science ®Google Scholar
• Shbeeb M, Uramoto KM, Gibson LE, O’Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmstead County, Minnesota, USA, 1982–1991. J. Rheumatol.27, 1247–1250 (2000).
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Gladman DD, Mease PJ et al. Epidemiology of psoriatic arthritis in the United States population. J. Amer. Acad. Dermatol.53, 573–577 (2005).
   PubMed Web of Science ®Google Scholar
• Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum.40, 1868–1872 (1997).
   PubMed Web of Science ®Google Scholar
• Ali Y, Tom BD, Schentag CT, Farewell VT, Gladman DD. Improved survival in psoriatic arthritis with calendar time. Arthritis Rheum.56(8), 2708–2714 (2007).
   PubMed Web of Science ®Google Scholar
• Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum.41, 1103–1110 (1998).
   PubMed Web of Science ®Google Scholar
• Gladman DD, Brockbank J. Psoriatic arthritis. Expert Opin. Invest. Drugs9, 1511–1522 (2000).
   PubMed Web of Science ®Google Scholar
• McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology42, 778–783 (2003).
   PubMed Web of Science ®Google Scholar
• Mease P, Goffe BS. Diagnosis and treatment of psoriatic arthritis. J. Am. Acad. Dermatol.52, 1–19 (2005).
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Ritchlin CT et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum.52(10), 3279–3289 (2005).
   PubMed Web of Science ®Google Scholar
• Gladman DD, Mease PJ, Ritchlin CT et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum.56(2), 476–488 (2007).
   PubMed Web of Science ®Google Scholar
• Maksymowych WP. Ankylosing spondylitis. In: Conn’s Current Therapy. Rakel RE, Bope ET (Eds.) WB Saunders Company, PA, USA, 1021–1023 (2001).
   Google Scholar
• Gladman DD. Clinical aspects of spondyloarthropathies. Am. J. Med. Sci.316, 234–238 (1998).
   PubMed Web of Science ®Google Scholar
• Akkoc N, Khan MA. Overestimation of the prevalence of ankylosing spondylitis in the Berlin study: comment on the article by Braun et al.Arthritis Rheum.52, 4048–4049; author reply 4049–4050 (2005).
   PubMed Web of Science ®Google Scholar
• Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitisresults from the German rheumatological database. J. Rheumatol.27, 613–622 (2000).
   PubMed Web of Science ®Google Scholar
• Ward MM. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum.46, 223–231 (2002).
   PubMed Web of Science ®Google Scholar
• Brunner R, Kissling RO, Auckenthaler C, Fortin J. Clinical evaluation of ankylosing spondylitis in Switzerland. Pain Physician5(1), 49–56 (2002).
   PubMedGoogle Scholar
• Calin A, Elswood J, Rigg S et al. Ankylosing spondylitis: an analytical review of 1500 patients: the changing pattern of the disease. J. Rheumatol.15, 1234–1238 (1988).
   PubMedGoogle Scholar
• Polley HF, Slocumb CH. Rheumatoid spondylitis – a study of 1035 cases. Ann. Intern. Med.26, 240 (1947).
   PubMed Web of Science ®Google Scholar
• Braun J, Pincus T. Mortality, course of disease and prognosis of patients with ankylosing spondylitis. Clin. Exp. Rheumatol.20(Suppl. 28), S16–S22 (2002).
   PubMed Web of Science ®Google Scholar
• Wanders A, van der Heijde D, Landewé R et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis. Arthritis Rheum.52, 1756–1765 (2005).
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Kivitz A, Schiff MH et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ATLAS). Arthritis Rheum.54, 2136–2146 (2006).
   PubMed Web of Science ®Google Scholar
• Knutson D, Greenberg G, Cronau H. Management of Crohn’s disease – a practical approach. Am. Fam. Physician.68, 707–714, 717–718 (2003).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn W. The management of Crohn’s disease in adults. Am. J. Gastroenterol.96, 635–643 (2001).
   PubMed Web of Science ®Google Scholar
• Juillerat P, Mottet C, Froehlich F et al. Extraintestinal manifestations of Crohn’s disease. Digestion71, 31–36 (2005).
   PubMedGoogle Scholar
• Ashford D, Imhoff B, Angulo F; FoodNet Working Group. Over a half-million persons may have Crohn’s disease in the United States. Presented at: 39th Annual Meeting of the Infectious Diseases Society of America. San Francisco, CA, USA, 25–28 October 2001.
   Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (Adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology130, 323–333 (2006).
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology132(1), 52–65 (2007).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut56(9), 1232–1239 (2007).
   PubMed Web of Science ®Google Scholar
• Schiff MH, Burmester GR, Kent JD et al. Safety analyses of adalimumab (Humira®) in global clinical trials with US postmarketing surveillance of patients with rheumatoid arthritis. Ann. Rheum. Dis.65, 889–894 (2006).
   PubMed Web of Science ®Google Scholar
• Burmester GR, Gordon KB, Perez JL, Pangan AL. Adalimumab safety profile in global clinical trials and reduction in standard mortality rates across multiple indications. Presented at: 66th Annual American Academy of Dermatology. San Antonio, TX, USA 1–5 February 2008 (Poster P2604).
   Google Scholar
• Silman AJ, Petrie J, Hazleman B, Evans SJ. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann. Rheum. Dis.47(12), 988–992 (1988).
   PubMed Web of Science ®Google Scholar
• Baecklund E, Iliadou A, Askling J et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum.54(3), 692–701 (2006).
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum.50(6), 1740–1751 (2004).
   PubMed Web of Science ®Google Scholar
• Regier DA, Bansback N, Dar Santos A, Marra CA. Cost–effectiveness of tumor necrosis factor-a antagonists in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Expert Rev. Pharmacoeconomics Outcomes Res.7(2), 155–169 (2007).
   PubMedGoogle Scholar
• American College of Rheumatology. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum.36, 713–722 (1996).
   Google Scholar
• Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum.48(10), 2750–2762 (2003).
   PubMed Web of Science ®Google Scholar
• Spalding JR, Hay J. Cost effectiveness of tumor necrosis factor-a inhibitors as first-line agents in RA. Pharmacoeconomics24(12), 1221–1232 (2006).
   PubMed Web of Science ®Google Scholar
• Gabriel SE, Tugwell P, Drummond M. Progress towards an OMERACT-lLAR guideline for economic evaluations in rheumatology. Ann. Rheum. Dis.61(4), 370–373 (2002).
   PubMedGoogle Scholar
• Cost–effectiveness in Health and Medicine. Gold MR, Siegel JE, Russell LB, Weinstein MC (Eds). Oxford University Press, NY, USA (1996).
   Google Scholar
• Torrance GW, Tugwell P, Amoprosi S, Chartash E, Sengupta N. Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody plus methotrexate. Rheumatology43, 712–718 (2004).
   PubMed Web of Science ®Google Scholar
• Chiou C-F, Choi J, Reyes CM. Cost–effectiveness analysis of biological treatments for rheumatoid arthritis. Expert Rev. Pharmacoeconomics Outcomes Res.4(3), 307–315 (2004).
   PubMedGoogle Scholar
• Bansback N, Brennan A, Anis AH. A pharmacoeconomic review of adalimumab in the treatment of rheumatoid arthritis. Expert Rev. Pharmacoeconomics Outcomes Res.5(5), 519–529 (2005).
   PubMedGoogle Scholar
• Brazier J, Deverill M, Green C, Harper R, Booth A. A review of the use of health status measure in economic evaluation. Health Technol. Assess.3(9), 9 (1999).
   Google Scholar
• Bansback NJ, Brennan A, Ghatnekar O. Cost–effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann. Rheum. Dis.64, 995–1002 (2005).
   PubMed Web of Science ®Google Scholar
• Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M. Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data. Curr. Med. Res. Opin.23(8), 1749–1759 (2007).
   PubMed Web of Science ®Google Scholar
• Rubio-Terrés C, Ordovás Baines JP, Pla Poblador R et al. Use and cost of biological disease-modifying anti-rheumatic drugs in Spain (PRAXIS study). Farm Hosp.31(2), 78–92 (2007).
   PubMedGoogle Scholar
• Botteman MF, Hay JW, Luo MP et al. Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom. Rheumatology (Oxford)46(8), 1320–1328 (2007).
   PubMed Web of Science ®Google Scholar
• Maksymowych W, Rahman P, Keystone E et al. Efficacy of adalimumab in active ankylosing spondylitis (AS) – results of the Canadian AS Study. Arthritis Rheum.52(9 Suppl.), S217 (2005).
   Google Scholar
• Symmons DPM. Anti-tumour necrosis factor a therapy: can we afford it? Ann. Rheum. Dis.65, 969–970 (2005).
   Google Scholar
• Husted JA, Tom BD, Farewell VT, Schentag CT, Gladman DD. A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: does the effect change over time? Arthritis Rheum.56, 840–849 (2007).
   PubMed Web of Science ®Google Scholar
• Lu CY, Williams KM, Day RO. The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines. Aust. New Zealand Health Policy4, 2 (2007).
   PubMedGoogle Scholar
• Brennan A, Bansback N, Nixon R et al. Modelling the cost effectiveness of TNF-a antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology46, 1345–1354 (2007).
   PubMed Web of Science ®Google Scholar
• First DataBank’s National Drug Data File Plus (NDDF Plus) [electronic database]. First DataBank, San Bruno, CA, USA (2005).
   Google Scholar
• Express Scripts Drug Trend 2002 Report. Express Scripts Inc., Maryland Heights, MO, USA (2003).
   Google Scholar
• Physicians’ Fee and Coding Guide (16th Edition). MAG Mutual Healthcare Solutions Inc., Duluth, GA, USA (2005).
   Google Scholar
• Jobanputra P, Barton P. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol. Assess.6, 1–99 (2002).
   PubMedGoogle Scholar